Petrelintide — compound monograph
Long-acting amylin analogue. Phase 2. The Institute assesses 1 outcome for this compound and grades the strongest at low certainty.
§1Identification and status
§1.1Nomenclature
- Preferred name
- Petrelintide
- Compound class
- Long-acting amylin analogue
- Assessment series
- Amylin analogues
- Synonyms and codes
- ZP8396 · petrelintide (INN)
- Route as evaluated
- Subcutaneous once weekly
§1.2Chemistry
Chemical identifiers are reproduced where they are public. Where a structure has not been published the monograph records not disclosed rather than constructing one.[1]
- CAS registry number
- not assigned in public records
- Molecular formula
- not published
- Average mass
- not published
- Monoisotopic mass
- not published
- ATC classification
- not assigned
§1.3Sequence and structural notes
Developed on the premise that amylin receptor agonism alone may produce weight reduction with better gastrointestinal tolerability than incretin receptor agonism. The full sequence is not public.
§1.4Assessment status
The Institute assesses Petrelintide across 1 indication and grades the strongest of them at low certainty. In exploratory clinical development.
Table 1. Assessed outcomes for Petrelintide, ordered by certainty. Each row links to the per-indication evidence extract.
| Indication | Effect as recorded | Certainty | Trials |
|---|---|---|---|
| Obesity and overweight in adults | −8.6 % body weight at 16 weeks in a phase 1b multiple-ascending-dose study versus −1.7 % with placebo | Low | 2 |
| Effects are reproduced as the contributing trials reported them. Where a confidence interval is held it appears on the per-indication extract rather than in this summary table. | |||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.